(PDF/179.22 KB) The safety profile of the medicine is considered acceptable. /MediaBox [0 0 612 792] (PDF/184.35 KB) In the body, fluorouracil takes the place of pyrimidine and interferes with the enzymes involved in making new DNA. (PDF/160.26 KB) (PDF/80.45 KB) (PDF/155.08 KB) (PDF/146.06 KB) /F3 12 0 R

Roche Laboratories, Nutley, NJ. (PDF/157.08 KB) (PDF/506.61 KB) r�ՠl�`��8����2�M����-rZ?k԰�r���[���kcF�%}^2�dp b�%L��� �M��1�ަ(]

(PDF/153.28 KB) (PDF/536.1 KB)

(PDF/141.88 KB)

(PDF/42.34 KB) (PDF/151.95 KB)



(PDF/179.14 KB) (PDF/142.69 KB) (PDF/182.21 KB) XELODA was non-inferior to 5- fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). (PDF/155.31 KB) (PDF/402.5 KB) (PDF/155.85 KB) (PDF/170.51 KB) (PDF/183.67 KB) (PDF/500.33 KB) (PDF/15.34 KB) (PDF/15.09 KB) (PDF/157.08 KB) (PDF/75.69 KB) (PDF/75.69 KB) (PDF/15.02 KB)


Uracil Mustard (uracil mustard)."

(PDF/414.74 KB) EMA is in the process of making appropriate changes to this website. (PDF/506.61 KB) /F1 6 0 R

(PDF/536.1 KB) (PDF/77.68 KB) (PDF/159.55 KB) (PDF/392.59 KB)

(PDF/45.91 KB)

(PDF/15.33 KB) (PDF/15.57 KB) >> 4 0 obj

(PDF/184.35 KB) (PDF/14.8 KB) (PDF/618.39 KB) (PDF/591.26 KB) For the full list of side effects reported with Xeloda, see the package leaflet.Xeloda must not be used in people who may be hypersensitive (allergic) to capecitabine, to any of the other ingredients, or to fluorouracil.

(PDF/14.8 KB)

(PDF/193.75 KB)
(PDF/143.26 KB)

(PDF/14.86 KB) Vepesid (etoposide)." (PDF/15.02 KB) (PDF/665.09 KB) (PDF/180.59 KB) Side effects reported with Xeloda are carefully evaluated and any necessary action taken to protect patients.Xeloda received a marketing authorisation valid throughout the EU on 2 February 2001.Please note that the size of the above document can exceed 50 pages.You are therefore advised to be selective about which sections or pages you wish to print.This medicine is authorised for use in the European Union.